Arbutus Biopharma Corporation（简称Arbutus Biopharma）公布了一项收购提议，其每股收购价格设定在5.00美元至5.75美元之间，且全部以现金形式支付。
这一报价区间明确了收购方愿意支付的价格范围——下限为每股5.00美元，上限则不超过每股5.75美元。值得注意的是，整个交易将以全现金方式完成，这为股东提供了明确的流动性预期。
具体而言，收购方给出的报价条件清晰而直接：每股价格不会低于5.00美元，同时也不会超越5.75美元的上限。此举展现了收购方对交易结构的审慎考量，同时也为市场参与者提供了可参考的定价基准。
在现金收购的框架下，这一价格区间的设定反映了对当前估值及市场环境的综合权衡，既保证了收购的吸引力，又控制了潜在的财务风险。股东们将有机会在这一既定范围内，根据自身判断做出相应决策。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.